UK's NASH rates as high as 12%

13 April 2018
perspectum

British tech firm Perspectum Diagnostics has revealed data that suggests as many as 12% of adults in the UK may be suffering from non-alcoholic steatohepatitis (NASH).

The data, presented to the International Liver Congress in Paris, was drawn from the medical database UK Biobank. It suggests that the prevalence of NASH in the UK may be as high as 12%, a significantly larger figure than the 2% previously estimated.

This is in part due to the difficulty of diagnosing sufferers. The disease is typically symptomless until it progresses into its advanced stages, and the only way to detect it before a patient becomes symptomatic is to extract cells from the liver. Some patients may reject even this procedure, as there is no treatment available if something is found.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical